BioMotiv, Dual Therapeutics, Icahn School of Medicine at Mount Sinai deal

BioMotiv and the Icahn School of Medicine launched Dual Therapeutics to develop therapeutics to treat prostate and lung cancer and acute lymphoblastic leukemia (ALL). Dual has an exclusive license to undisclosed IP from the Icahn School of Medicine and received funding from BioMotiv. The Icahn School of Medicine and BioMotiv declined to disclose details, and Dual Therapeutics could not be reached. ...